GlassScriptPhysician profile
Xenos L Mason
NPI 1619358801
$53,451.13
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $80.27 · 2021: $438 · 2022: $155 · 2023: $16K · 2024: $24K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $6,133 · Food and Beverage: $3,920 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,502.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,587.50 |
| Travel and Lodging | $6,132.58 |
| Food and Beverage | $3,919.77 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,785.42 | 2019-2025 | Infinity |
| Janssen Research & Development, LLC | $20,048.66 | 2024-2025 | Carvykti, Tecvayli |
| Boston Scientific Corporation | $9,919.09 | 2019-2025 | Vercise, General - Dbs |
| Medtronic, INC. | $843.77 | 2023 | Percept PC Brainsense |
| Janssen Global Services, LLC | $675.00 | 2025 | Carvykti, Darzalex, Tecvayli |
| Teva Pharmaceuticals USA, INC. | $153.69 | 2023-2025 | Austedo Xr, Austedo Xr |
| Cipher Pharmaceuticals US LLC | $23.01 | 2025 | Spinosad, Natroba |
| Travere Therapeutics, INC. | $2.49 | 2022-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xenos Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.